Techspec schreef op 25 januari 2019 12:25:
Ter informatie;
Case report 20 sep 2018!
RhC1inh (Ruconest) blijkt veel goedkoper en effectief te zijn voor HAE profylaxe t.o.v. een bloed plasma gerelateerde C1 inhibitor!
www.tandfonline.com/doi/full/10.1080/...Conclusions: rhC1-INH prophylaxis for HAE reduced occurrence of ER visits and provided potential cost benefits for both drug costs and medical utilization.
Patient began prophylaxis TIW with rhC1-INH 2100?IU (Ruconest) with an annual cost savings of $400,660 versus pdC1-INH. From initiation of rhC1-INH to October 2017, patient required only 1 ER visit.